Open Trials - In Follow Up - TROG Cancer Research

BIG 307/TROG 07.01 – DCIS

A randomised phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in-situ (DCIS) of the breast

TROG 08.06 – STARS

A Randomised comparison of anastrozole commenced before and continuing during adjuvant radiotherapy for breast cancer versus anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy.

TROG 12.02 – PET LABRADOR

PET scans for locally advanced breast cancer and diagnostic MRI to determine the extent of operation and radiotherapy

TROG 15.03/ANZUP 16001 – FASTRACK II

Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney - a Phase II Clinical Trial

TROG 20.01 – CHEST RT

Chemotherapy Immunotherapy in Extensive Stage Small Cell with Thoracic Radiation therapy

USYD/TROG 17.03 – LARK

Liver Ablative Radiotherapy utilizing Kilovoltage intrafraction monitoring (KIM)

EORTC 13.08/TROG 15.02 – ROAM

Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial

EORTC 22033-26033/TROG 06.01 (Low Grade Glioma)

Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study

ICR-CTSU/2015/15552/TROG 16.03 – CORE

A randomised trial of Conventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases

TROG 14.02 – RAIDER

A randomised phase II trial of adaptive image guided standard or dose escalated radiotherapy in the treatment of transitional cell carcinoma of the bladder

AGITG AG0407GR/TROG 08.08 – TOPGEAR

A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer.

ANZUP 1801/TROG 21.02 DASL-HiCaP

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate. A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.

R2810-ONC-1788/TROG 17.11 – CPOST

A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma

TROG 14.01 – ENZARAD

Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer

E33039 IAEA NPC

A Situation Analysis of National Radiotherapy Resources and Patterns of Care for Patients with Nasopharyngeal Carcinoma in Low-Middle Income Countries: Can Enhancing the Quality of Radiotherapy Planning Improve Outcomes

Open Trials – In Follow Up